| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/25/2023 | 93.45% | Morgan Stanley | $14 → $3.25 | Downgrades | Overweight → Equal-Weight |
| 08/18/2023 | 733.33% | Morgan Stanley | $15 → $14 | Maintains | Overweight |
| 06/13/2023 | 792.86% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/16/2023 | 792.86% | Morgan Stanley | $16 → $15 | Maintains | Overweight |
| 03/29/2023 | 792.86% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 03/27/2023 | 792.86% | HC Wainwright & Co. | $20 → $15 | Maintains | Buy |
| 03/21/2023 | 1090.48% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 08/15/2022 | 852.38% | Morgan Stanley | $19 → $16 | Maintains | Overweight |
| 08/11/2022 | 1090.48% | HC Wainwright & Co. | $22 → $20 | Maintains | Buy |
| 05/17/2022 | 1030.95% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
| 05/13/2022 | 1209.52% | HC Wainwright & Co. | $23 → $22 | Maintains | Buy |
| 12/15/2021 | 1269.05% | HC Wainwright & Co. | $25 → $23 | Maintains | Buy |
| 05/25/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 05/25/2021 | 1566.67% | Jefferies | → $28 | Initiates Coverage On | → Buy |
| 05/25/2021 | 1209.52% | Morgan Stanley | → $22 | Initiates Coverage On | → Overweight |
| 05/24/2021 | 1388.1% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
What is the target price for Vaccitech (VACC)?
The latest price target for Vaccitech (NASDAQ: VACC) was reported by Morgan Stanley on September 25, 2023. The analyst firm set a price target for $3.25 expecting VACC to rise to within 12 months (a possible 93.45% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vaccitech (VACC)?
The latest analyst rating for Vaccitech (NASDAQ: VACC) was provided by Morgan Stanley, and Vaccitech downgraded their equal-weight rating.
When is the next analyst rating going to be posted or updated for Vaccitech (VACC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vaccitech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vaccitech was filed on September 25, 2023 so you should expect the next rating to be made available sometime around September 25, 2024.
Is the Analyst Rating Vaccitech (VACC) correct?
While ratings are subjective and will change, the latest Vaccitech (VACC) rating was a downgraded with a price target of $14.00 to $3.25. The current price Vaccitech (VACC) is trading at is $1.68, which is out of the analyst's predicted range.